Generate Biomedicines, Inc. Common Stock (GENB)vsNovartis AG ADR (NVS)
GENB
Generate Biomedicines, Inc. Common Stock
$15.30
-0.78%
HEALTHCARE · Cap: $1.97B
NVS
Novartis AG ADR
$148.34
+1.95%
HEALTHCARE · Cap: $275.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 177299% more annual revenue ($56.58B vs $31.89M). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
GENB
Avoid16
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GENB.
Margin of Safety
-52.0%
Fair Value
$109.95
Current Price
$148.34
$38.39 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Grey zone — moderate risk
Expensive relative to growth rate
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : GENB
GENB has a balanced fundamental profile.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : GENB
The primary concerns for GENB are Revenue Growth, EPS Growth, Market Cap.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
GENB profiles as a value stock while NVS is a declining play — different risk/reward profiles.
GENB is growing revenue faster at 0.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 16/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Generate Biomedicines, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Generate Biomedicines, Inc. is an innovative biotechnology company focused on harnessing the power of genetic engineering to develop protein therapeutics for a range of diseases. By leveraging advanced artificial intelligence and machine learning technologies, Generate Biomedicines aims to streamline the drug discovery process, significantly reducing time and costs associated with traditional methods. The company's proprietary platform enables the rapid design and optimization of therapeutic proteins, positioning it at the forefront of the biopharmaceutical industry. With a strong commitment to improving patient outcomes, Generate Biomedicines continues to expand its pipeline and collaborate with leading partners to bring transformative treatments to market.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?